C Burri

Summary

Affiliation: University of Basel
Country: Switzerland

Publications

  1. pmc Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring
    Andrea Kuemmerle
    Swiss Tropical and Public Health Institute, Department of Medicines Research, Basel, Switzerland
    Malar J 10:57. 2011
  2. doi request reprint Chemotherapy against human African trypanosomiasis: is there a road to success?
    Christian Burri
    Swiss Tropical and Public Health Institute, Department of Medicines Research, Basel, Switzerland
    Parasitology 137:1987-94. 2010
  3. ncbi request reprint Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness
    C Schmid
    Swiss Tropical Institute, 4002 Basel, Switzerland
    Lancet 364:789-90. 2004
  4. ncbi request reprint Eflornithine for the treatment of human African trypanosomiasis
    Christian Burri
    Swiss Tropical Institute, Swiss Center for International Health, Socinstrasse 57, P O Box, 4002 Basel, Switzerland
    Parasitol Res 90:S49-52. 2003
  5. ncbi request reprint Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment
    C Burri
    Department of Medical Parasitology and Infection Biology, Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 6:412-20. 2001
  6. ncbi request reprint Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial
    C Burri
    Swiss Tropical Institute, Basel
    Lancet 355:1419-25. 2000
  7. ncbi request reprint The phenomenon of treatment failures in Human African Trypanosomiasis
    R Brun
    Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 6:906-14. 2001
  8. ncbi request reprint Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis
    J Blum
    Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 6:390-400. 2001
  9. ncbi request reprint The story of CGP 40 215: studies on its efficacy and pharmacokinetics in African green monkey infected with Trypanosoma brucei rhodesiense
    R Brun
    Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 6:362-8. 2001
  10. ncbi request reprint Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug
    J Blum
    Swiss Tropical Institute, Basel, Switzerland
    Swiss Med Wkly 132:51-6. 2002

Collaborators

Detail Information

Publications22

  1. pmc Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring
    Andrea Kuemmerle
    Swiss Tropical and Public Health Institute, Department of Medicines Research, Basel, Switzerland
    Malar J 10:57. 2011
    ..This project was undertaken to profile the provenance of the pharmacovigilance reporting of all anti-malarials, including ACT to the WHO adverse drug reaction (ADR) database (Vigibase™) over the past 40 years...
  2. doi request reprint Chemotherapy against human African trypanosomiasis: is there a road to success?
    Christian Burri
    Swiss Tropical and Public Health Institute, Department of Medicines Research, Basel, Switzerland
    Parasitology 137:1987-94. 2010
    ..This review summarizes the key information about the existing drugs and gives a comprehensive summary about the recent and currently ongoing efforts towards new drugs...
  3. ncbi request reprint Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness
    C Schmid
    Swiss Tropical Institute, 4002 Basel, Switzerland
    Lancet 364:789-90. 2004
    ..After 2 years, 23 (5%) relapsing patients were reported, 11 (5%) in the standard treatment group and 12 (6%) in the new group. The results at the 2-year follow-up support and strengthen our previous findings...
  4. ncbi request reprint Eflornithine for the treatment of human African trypanosomiasis
    Christian Burri
    Swiss Tropical Institute, Swiss Center for International Health, Socinstrasse 57, P O Box, 4002 Basel, Switzerland
    Parasitol Res 90:S49-52. 2003
    ..Based on its trypanostatic rather than trypanocidal mode of action, it is a rather slow-acting drug...
  5. ncbi request reprint Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment
    C Burri
    Department of Medical Parasitology and Infection Biology, Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 6:412-20. 2001
    ..Serum and CSF concentrations for all patients were in the expected range. This result indicates that other underlying factors are responsible for treatment failures...
  6. ncbi request reprint Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial
    C Burri
    Swiss Tropical Institute, Basel
    Lancet 355:1419-25. 2000
    ..Despite these problems, melarsoprol is likely to remain the drug of choice for the next decade. We therefore did a randomised trial comparing the standard treatment schedule with a new, concise regimen...
  7. ncbi request reprint The phenomenon of treatment failures in Human African Trypanosomiasis
    R Brun
    Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 6:906-14. 2001
    ..In conclusion, a combination of factors rather than a single one may be responsible for the phenomenon of melarsoprol treatment failures in T. b. gambiense patients...
  8. ncbi request reprint Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis
    J Blum
    Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 6:390-400. 2001
    ..5), headache (RR 2.5), bullous eruptions (RR 4.5) and systolic hypotension (RR 2.6) were associated with an increased risk for the occurrence of encephalopathic syndromes especially of the coma type...
  9. ncbi request reprint The story of CGP 40 215: studies on its efficacy and pharmacokinetics in African green monkey infected with Trypanosoma brucei rhodesiense
    R Brun
    Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 6:362-8. 2001
    ..As the majority of sleeping sickness patients seeking treatment are in the 2nd stage of the disease, further development of the compound was stopped...
  10. ncbi request reprint Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug
    J Blum
    Swiss Tropical Institute, Basel, Switzerland
    Swiss Med Wkly 132:51-6. 2002
    ..Statistical analysis yielded no significant differences for adverse events between the two treatment protocols. The new schedule reduces the amount and cost for the drug by about one third, and those for hospitalisation by about half...
  11. ncbi request reprint Evaluation of quinolone derivatives for antitrypanosomal activity
    J Keiser
    Department of Medical Parasitology and Infection Biology, Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 6:369-89. 2001
    ....
  12. ncbi request reprint New drugs for the treatment of human African trypanosomiasis: research and development
    J Keiser
    Swiss Tropical Institute, PO Box, CH-4002, Basel, Switzerland
    Trends Parasitol 17:42-9. 2001
    ..The absence of compounds in clinical development Phases I-III indicates no new drugs will become available in the next few years...
  13. doi request reprint Human African trypanosomiasis
    Reto Brun
    Swiss Tropical Institute, Basel, Switzerland
    Lancet 375:148-59. 2010
    ..WHO has stated that if national control programmes, international organisations, research institutes, and philanthropic partners engage in concerted action, elimination of this disease might even be possible...
  14. doi request reprint Reflections on clinical research in sub-Saharan Africa
    Irene Kuepfer
    Swiss Tropical Institute, Pharmaceutical Medicine Unit, Basel, Switzerland
    Int J Parasitol 39:947-54. 2009
    ..Given those short-comings we recommend minimum standards needed at the local, national and sponsor levels to provide GCP-compliant clinical research...
  15. doi request reprint Cardiac involvement in African and American trypanosomiasis
    Johannes A Blum
    Swiss Tropical Institute, Basel, Switzerland
    Lancet Infect Dis 8:631-41. 2008
    ..HAT cardiopathy in general is benign and does not cause relevant congestive heart failure and subsides with treatment. We review the differences between the American and African trypanosomiasis with the main focus on the heart...
  16. ncbi request reprint Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis)
    Johannes A Blum
    Swiss Tropical Institute, Basel, Switzerland
    Trop Med Int Health 12:1422-32. 2007
    ....
  17. ncbi request reprint Sleeping glands? - The role of endocrine disorders in sleeping sickness (T.b. gambiense Human African Trypanosomiasis)
    Johannes A Blum
    Swiss Tropical Institute, Socinstrasse 57, CH 4002 Basel, Switzerland
    Acta Trop 104:16-24. 2007
    ..However, a transitory adrenal insufficiency was suspected in 8% of HAT patients at admission and in 9% at discharge. All values were normal at follow-up 3 months later...
  18. ncbi request reprint Clinical aspects of 2541 patients with second stage human African trypanosomiasis
    Johannes Blum
    Swiss Tropical Institute, Medical and Diagnostic Services, Socinstrasse 57, 4002 Basel, Switzerland
    Acta Trop 97:55-64. 2006
    ..4-61.2%). Fever is most frequently reported in children between 2 and 14 years of age (26.1-28.7%) and malnutrition is significantly more frequently observed in children of all ages (43-56%) than in adults (23.5%)...
  19. pmc Cardiac alterations in human African trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment
    Johannes A Blum
    Swiss Tropical Institute, Basel, Switzerland
    PLoS Negl Trop Dis 3:e383. 2009
    ....
  20. ncbi request reprint Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II)
    Caecilia Schmid
    Swiss Tropical Institute, Basel
    J Infect Dis 191:1922-31. 2005
    ..A previous trial demonstrated the safety and efficacy of a 10-day treatment schedule. We demonstrate the effectiveness of this schedule in a noncontrolled, multinational drug-utilization study...
  21. ncbi request reprint Treatment of human African trypanosomiasis--present situation and needs for research and development
    Dominique Legros
    Epicentre, Paris, France
    Lancet Infect Dis 2:437-40. 2002
    ..At the same time, on a long term basis, ambitious research programmes for new compounds must be supported to ensure the sustainable development of new drugs...
  22. pmc Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions
    Elizabeth Nenortas
    Departments of Medicine and of Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore, Maryland 21205, USA
    Antimicrob Agents Chemother 47:3015-7. 2003
    ..These compounds trap protein-DNA complexes and inhibit nucleic acid biosynthesis in trypanosomes, characteristics of topoisomerase II inhibition...